Yourgene Health plc
(“Yourgene” or the “Company”)
Strategic partnership extended with Ambry Genetics
Expanding market access of technology
Manchester, UK – 25 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the Company has extended its strategic partnership with Ambry Genetics (‘Ambry’), a leading US precision medicine company, with a new Genomic Services collaboration. The new agreement will allow both companies access to each other’s technology and assays, expanding market access and penetration for both.
On 9 June 2021 Yourgene announced a multi-year licence and supply agreement with an unnamed US partner (the ‘Partner’) for access to the Company’s Noninvasive prenatal testing (NIPT) technology which came into effect on 1 April 2022. Yourgene can now confirm that the Partner is Ambry Genetics, a part of REALM IDx, Inc.
The agreement will enable the development of NIPT-related solutions as a part of Ambry’s Women’s Health portfolio expansion. Along with carrier screening, the portfolio will include Ambry’s CARE (Comprehensive Assessment Risk and Education) Program, a digital tool that provides a streamlined, end-to-end solution for physicians to provide risk screening and education on genetic testing, as well as facilitate test ordering, result reporting and access to genetic counselors.
Currently, Ambry’s CARE Program is being used to help identify patients at higher risk of developing cancer, but it will be expanded to include NIPT and Carrier Screening to provide physicians one easy-to-use platform with a comprehensive set of genetic testing, education and support options for their patients.
“To truly add value for physicians, you need to have a robust screening technology along with a delivery program that helps to educate and ensure that patients understand the testing that they are being offered” said Tom Schoenherr, Chief Executive Officer of Ambry Genetics. “We believe the partnership with Yourgene and our CARE Program will help to standardize informed care and remove disparities in its delivery.”
Yourgene expects that this partnership will underpin its future growth and create a greater number of commercial opportunities for both companies.
Lyn Rees, Chief Executive Officer, commented: “This is a multi-level partnership with a leader in the field of precision medicine. Ambry will provide an addressable US market for NIPT and a range of class leading oncology products and services to bring to our recently expanded UK based genomic services footprint. We very much look forward to strengthening and broadening our relationship with Ambry, cementing our relationship with this prestigious US company.”
This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Tel: +44 (0)161 669 8122
|Cairn Financial Advisers LLP (NOMAD)|
Liam Murray / James Caithie / Ludovico Lazzaretti
|Tel: +44 (0)20 7213 0880|
|Singer Capital Markets (Joint Corporate Broker)|
Aubrey Powell / Tom Salvesen / George Tzimas
|Tel: +44 (0)20 7496 3000|
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison
Tel: +44 (0)20 7710 7600
Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Lianne Applegarth / Alice Woodings
Tel: +44 (0)20 7933 8780 or firstname.lastname@example.org
Mob: 07980 541 893 Mob: 07584 391 303 Mob: 07407 804 654
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling genomic medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
About Ambry Genetics
Ambry Genetics, a part of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
REALM IDx Communications Director